Inhibits PAF-induced platelet aggregation (IC50=8.4 µM) and collagen-induced aggregation (IC50=84.2 µM) with no effect on arachidonic acid or ADP induced aggregation. Inhibits PAF-induced bronchoconstriction in vivo in the guinea-pig (69% at 1.0 mg/kg).
Product Details
Alternative Name: | FR-49175 |
|
Formula: | C15H20N2O4S2 |
|
MW: | 356.5 |
|
CAS: | 74149-38-5 |
|
Purity: | ≥98% (TLC) |
|
Appearance: | White solid. |
|
Solubility: | Soluble in DMSO (25mg/ml) and ethanol (25mg/ml). |
|
Shipping: | Ambient |
|
Long Term Storage: | -20°C |
|
Use/Stability: | Store, as supplied, at -20ºC for up to 1 year. Store solutions at -20ºC for up to 3 months. |
|
Regulatory Status: | RUO - Research Use Only |
|
Please mouse over
Product Literature References
At the metal–metabolite interface in Aspergillus fumigatus: towards untangling the intersecting roles of zinc and gliotoxin: A.M. Traynor, et al.; Microbiology
167, 1106 (2021),
Abstract;
NF-kappaB activation is a critical regulator of human granulocyte apoptosis in vitro: C. Ward, et al.; J. Biol. Chem.
274, 4309 (1999),
Abstract;
The immunosuppressive fungal metabolite gliotoxin specifically inhibits transcription factor NF-kappaB: H.L. Pahl, et al.; J. Exp. Med.
183, 1829 (1996),
Abstract;
Studies of platelet activating factor (PAF) antagonists from microbial products. I. Bisdethiobis(methylthio)gliotoxin and its derivatives: M. Okamoto, et al.; Chem. Pharm. Bull. (Tokyo)
34, 340 (1986),
Abstract;
Studies of platelet activating factor (PAF) antagonists from microbial products. II. Pharmacological studies of FR-49175 in animal models: M. Okamoto, et al.; Chem. Pharm. Bull. (Tokyo)
34, 345 (1986),
Abstract;